-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $103

Benzinga·11/13/2026 17:47:40
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $119 to $103.